VITALMEDIX

VitalMedix Inc. engages in the research and development of biopharmaceuticals for sustaining cellular function and protecting cells during and after hemorrhagic shock in the United States. The company develops Tamiasyn, a biopharmaceutical that potentially allows the human body to endure severe blood loss for an extended period of time, as well as inhibits human organ damage during the resuscitation process. It also develops a hemorrhagic shock treatment system. The company was founded in 2005 and is based in Minneapolis, Minnesota.